Infudopa IntraV (levodopa/carbidopa IV) / Dizlin - LARVOL DELTA

Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion. (PubMed, Mov Disord Clin Pract) - "Although DIZ101 or DIZ102 causes approximately four times higher plasma carbidopa levels than LCIG, patients responded equally well to all treatments. The results do not indicate that high plasma carbidopa levels hamper the motor efficacy of levodopa."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Subcutaneous Levodopa: A New Engine for the Vintage Molecule. (PubMed, Neurol Ther) - "The key focus of this review is placed on subcutaneous foslevodopa/foscarbidopa (Foslevodopa/foscarbidopa) infusion, showcasing its recent clinical availability and efficacy in providing continuous levodopa delivery. While providing an overview of the other non-oral levodopa-based CDD systems, such as intrajejunal levodopa-carbidopa infusion and levodopa-entacapone-carbidopa infusion, we highlight the current promising evidence for Foslevodopa/foscarbidopa to improve, for example, "on time" without troublesome dyskinesia and reducing "off time" in people with advanced PD...While these advancements present new therapeutic avenues, long-term observational studies are warranted to elucidate their impact on existing PD therapies. Overall, this review provides insights into the evolving landscape of non-oral CDD therapies and offers a pragmatic approach for their integration into clinical practice."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa (MDS Congress 2023) - "There was no observable trend for lower levodopa efficacy on motor symptoms, despite the higher CD concentrations with DIZ101 and DIZ102 compared to LCIG [1]. This indicates, in line with previous reports [2][3], that high blood levels (up to approximately 800 ng/mL) of carbidopa do not reduce the CNS effect of levodopa."

CNS Disorders • Parkinson's Disease

Dizlin Pharmaceuticals publishes data from pharmacokinetic study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology (PRNewswire) - P1 | N=25 | NCT03419806 | Sponsor: Vastra Gotaland Region |"Dizlin Pharmaceuticals AB...announces that an article has been published in Neurology®, from the American Academy of Neurology...In a pharmacokinetic cross-over study comprising 18 evaluable subjects with advanced Parkinson´s disease, levodopa/carbidopa solutions with a pH of 5.5 were produced by continuous buffering shortly prior to intravenous (DIZ101) or subcutaneous (DIZ102) administration....'The outcome shows that subcutaneous administration of a continuously buffered levodopa solution could be a feasible technique to safely and rapidly obtain high and stable levodopa levels in patients with Parkinson´s disease'....'The results suggest that DIZ102 (Infudopa SubC™), administered by means of a portable twin pump, may serve as a levodopa/carbidopa monotherapy for patients requiring high levodopa levels but experience motor fluctuations when receiving oral administration.'"

P1 data • PK/PD data • CNS Disorders • Parkinson's Disease